Navigation Links
Top 10 Drug Delivery Technologies (2010 - 2015)
Date:9/18/2012

NEW YORK, Sept. 18, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Top 10 Drug Delivery Technologies (2010 - 2015)

http://www.reportlinker.com/p0407271/Top-10-Drug-Delivery-Technologies-2010---2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

STUDY GOALS AND OBJECTIVES -To define and measure drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics and others.

-To identify major drivers and restraints of the market

-To evaluate comprehensively all drug delivery technologies and benchmark them against various parameters to identify top ten technologies.

-To identify and analyze comprehensively market structure with respect to the factors influencing market growth and industry specific challenges.

-To analyze trends and forecasts of drug delivery market and its segments

-To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.

-To analyze opportunities in the market for stakeholders

-To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market

-To understand regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.

-To analyze and forecast revenues of market segments with respect to geographies (North America, Europe, Asia and Rest of the World

-To provide comprehensive analysis of top players in the drug delivery technology market.

-To effectively scope out and justify evaluation and provide sufficient basis of ranking top ten drug delivery technologies.

REASONS FOR DOING THE STUDY More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body (pharmacokinetics) therefore signifying the importance of drug delivery systems. Rapid enhancements in drug discovery technologies have lead to developments in proteomics and genomics and had a greater impact on drug delivery technology market. The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.SCOPE AND FORMAT Top 10 Drug Delivery Technologies Market research report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are:

-Oral drug delivery technologies

-Injectable drug delivery technologies

-Pulmonary drug delivery technologies

--Transdermal drug delivery technologies

Other drug delivery technologies

The report also focuses on the emerging drug delivery technologies and mechanisms.

INTENDED AUDIENCES

-Drug delivery technology – manufacturers, suppliers and dealers-Pharmaceutical and biotech companies-Healthcare providers-Potential investors in the drug delivery technology market

INFORMATION SOURCES

Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides 40 companies. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.

TABLE OF CONTENTS

EXECUTIVE SUMMARY OBJECTIVEMARKET SCENARIOEMERGING TECHNOLOGIES

1 INTRODUCTION

1.1 KEY TAKE-AWAYS

1.2 REPORT DESCRIPTION

1.3 MARKETS COVERED

1.4 STAKEHOLDERS

1.5 RESEARCH METHODOLOGY

2 SUMMARY

3 MARKET OVERVIEW

3.1 INTRODUCTION

3.2 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE

3.3 STAKEHOLDERS

3.4 CHALLENGES

3.4.1 GOVERNMENT REGULATIONS

3.4.2 PRICING PRESSURE, REIMBURSEMENTS, & THIRD-PARTY DEPENDENCE

3.4.3 PATENT LITIGATIONS

3.4.4 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES

3.5 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS

3.6 PATENT ANALYSIS

4 MARKET DYNAMICS4.1 INTRODUCTION4.2 DRIVERS4.2.1 PATENT EXPIRATION OF DRUGS4.2.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS & BIOPHARMACEUTICALS4.2.3 REDUCE ATTRITION RATES & FASTER DRUG DISCOVERY/DEVELOPMENT PROCESSES4.2.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY4.2.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES4.3 RESTRAINTS4.3.1 DRUG FAILURES RAISE CONCERNS ON ROI4.3.2 U.S. HEALTHCARE REFORMS4.4 OPPORTUNITIES4.4.1 HOME-CARE DRUG DELIVERY DEVICES & SELF-ADMINISTRATION4.4.2 NICHE THERAPEUTIC AREAS4.4.3 WELLNESS PRODUCTS

5 CONTROLLED RELEASE TECHNOLOGY

5.1 INTRODUCTION

5.1.1 KEY MARKET PLAYERS

5.2 DRIVERS

5.2.1 CONTROLLED RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS

5.2.2 ONCE-A-DAY FORMULATIONS

5.2.3 COST EFFECTIVE

5.3 RESTRAINTS

5.3.1 LIMITED NUMBER OF MATERIALS

5.3.2 TECHNICAL BARRIERS

5.4 OPPORTUNITIES

5.4.1 PARTICULATE & CHRONOPHARMACOKINETIC SYSTEMS

5.4.2 MUCOADHESIVE DRUG DELIVERY

5.5 BIODEGRADABLE POLYMERS

5.6 HYDROGEL

5.7 MULTIPARTICULATE BEAD SYSTEMS

5.8 ION EXCHANGE RESINS

5.9 OSMOTIC PRESSURE CONTROLLED SYSTEMS

5.10 DISSOLUTION/DIFFUSION SYSTEMS

5.10.1 MATRIX SYSTEMS

5.10.2 RESERVOIR SYSTEMS

5.11 OTHERS

5.12 REGULATORY ENVIRONMENT

5.13 CONTROLLED RELEASE VS IMMEDIATE RELEASE FORMULATIONS

5.14 INNOVATIONS IN CONTROLLED RELEASE TECHNOLOGIES

5.15 BURNING ISSUES

5.16 WINNING IMPERATIVES

5.17 COMPETITIVE DEVELOPMENTS

6 TARGETED DELIVERY6.1 INTRODUCTION6.1.1 KEY MARKET PLAYERS6.2 DRIVERS & RESTRAINTS6.2.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS6.2.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR6.2.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS6.3 OPPORTUNITY6.3.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS6.4 TARGETING LIGANDS6.4.1.1 Antibody fragment drug conjugate delivery6.4.1.2 Antibody directed enzyme prodrug targeted delivery6.4.1.3 Peptide-targeted delivery6.4.1.4 Small molecule conjugate delivery6.4.1.5 Others6.5 NON-BIOLOGICAL TARGETING PLATFORMS6.6 CURRENTLY MARKETED TARGETED THERAPIES6.7 IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS6.8 INNOVATIONS6.9 INDUSTRY INSIGHTS6.10 WINNING IMPERATIVES

7 ENCAPSULATION TECHNOLOGIES

7.1 INTRODUCTION

7.1.1 KEY MARKET PLAYERS

7.2 DRIVERS & RESTRAINTS

7.2.1 ENHANCED BIOAVAILABILITY

7.2.2 EXTENSIVE USAGE IN TASTE MASKING & FASTER DISSOLVING PILLS

7.2.3 ECONOMICALLY FEASIBLE

7.2.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES

7.3 OPPORTUNITY

7.3.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS

7.4 TASTE MASKING

7.5 FAST DISSOLVING PILLS

7.6 EVOLUTION OF ENCAPSULATION TECHNOLOGIES

7.7 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY

7.8 INDUSTRY INSIGHTS

7.9 WINNING IMPERATIVES

7.10 COMPETITIVE DEVELOPMENTS

8 TOPICAL FORMULATIONS8.1 INTRODUCTION8.1.1 KEY MARKET PLAYERS8.2 DRIVERS & RESTRAINTS8.2.1 BURN & WOUND TREATMENT8.2.2 BYPASSING FIRST PASS EFFECT8.2.3 CONVENIENCE FACTOR8.2.4 USAGE IN LIMITED THERAPEUTIC AREAS8.3 OPPORTUNITY8.3.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS8.4 GEL TECHNOLOGY8.5 MICROEMULSIONS8.6 BIPHASIC SYSTEM8.7 OTHERS8.8 INDUSTRY INSIGHTS8.9 WINNING IMPERATIVES8.10 COMPETITIVE DEVELOPMENTS

9 INHALER TECHNOLOGY

9.1 INTRODUCTION

9.1.1 KEY MARKET PLAYERS

9.2 DRIVERS & RESTRAINTS

9.2.1 INCREASE IN ASTHMA & COPD PATIENTS

9.2.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN

9.2.3 EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY

9.2.4 FAILURE OF EXUBERA

9.3 OPPORTUNITY

9.3.1 APPLICATION IN NON-RESPIRATORY CONDITIONS

9.4 DRY POWDER INHALERS

9.5 METERED DOSE INHALERS

9.6 NEBULIZERS

9.7 EVOLUTION OF INHALER DEVICES

9.8 REGULATORY ENVIRONMENT

9.9 TECHNOLOGY INNOVATIONS

9.10 INDUSTRY INSIGHTS

9.11 WINNING IMPERATIVES

9.12 COMPETITIVE DEVELOPMENTS

10 INJECTABLE DRUG DELIVERY10.1 INJECTION DEVICES10.1.1 KEY MARKET DYNAMICS10.1.1.1 Drivers10.1.1.1.1 Growth of self-administration therapies10.1.1.1.2 Needle-stick legislation10.1.1.1.3 Increasing acceptance by physicians and patients10.1.1.1.4 Reducing cost of treatment10.1.1.2 Restraints10.1.1.2.1 Need of new drug formulation10.1.1.3 Opportunities10.1.1.3.1 Product differentiation through added functional features10.1.1.3.2 Expansion to new areas10.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE10.3 KEY DEVELOPMENTS10.3.1 DEVELOPMENT OF MICRONEEDLES10.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS10.4 CONVENTIONAL INJECTABLES10.5 PREFILLED SYRINGES (PFS)10.5.1 KEY MARKET DYNAMICS10.5.1.1 Drivers10.5.1.1.1 Growing market for self-injection devices10.5.1.1.2 Wastage control and cost reduction through less overfill10.5.1.1.3 Ease of manufacture & convenient usability10.5.1.2 Restraints10.5.1.2.1 Threat from needle-free devices10.5.1.2.2 Protecting product quality10.5.2 GLASS PFS10.5.3 PLASTIC PFS10.6 SELF INJECTION DEVICES10.6.1 AUTO INJECTORS10.6.1.1 Reusable auto-injectors10.6.1.2 Disposable auto-injectors10.6.2 PEN INJECTORS10.6.2.1 Reusable pen injectors10.6.2.2 Disposable pen injectors10.6.3 NEEDLE-FREE INJECTORS (NFI)10.6.3.1 Reusable NFIs10.6.3.2 Disposable NFIs10.7 OTHERS

11 TRANSDERMAL PATCH

11.1 INTRODUCTION

11.1.1 KEY MARKET PLAYERS

11.2 DRIVERS

11.2.1 REDUCED SIDE EFFECTS & BETTER EFFICACY

11.2.2 CONVENIENT & LESS PAINFUL

11.3 RESTRAINTS

11.3.1 RECALL OF DURAGESIC & NEGATIVE PUBLICITY OF ORTHO EVRA PATCH

11.3.2 LOW SKIN PERMEABILITY OF DRUGS

11.4 OPPORTUNITIES

11.4.1 NEW PRODUCTS

11.4.1.1 Contraceptive patch

11.4.1.2 Pain management patch

11.4.1.3 Estrogen/hormone replacement patch

11.5 INDUSTRY INSIGHTS

11.6 WINNING IMPERATIVES

11.7 COMPETITIVE DEVELOPMENTS

12 IMPLANTABLE DRUG DELIVERY12.1 INTRODUCTION12.2 DRIVERS & RESTRAINTS12.2.1 SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT12.2.2 DOSING ADMINISTRATION NOT REQUIRED12.2.3 INCONVENIENCE12.3 OPPORTUNITY12.3.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS12.4 CORONARY (DRUG ELUTING) STENTS12.5 IMPLANTABLE INFUSION PUMPS12.6 OCULAR IMPLANTS & OTHERS12.7 INDUSTRY INSIGHTS12.8 WINNING IMPERATIVES

13 LIPOSOMAL DRUG DELIVERY

13.1 INTRODUCTION

13.2 DRIVERS & RESTRAINTS

13.2.1 ENHANCED USAGE IN CANCER

13.2.2 EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS

13.2.3 SIDE EFFECTS

13.3 OPPORTUNITY

13.3.1 NANOSCALE LIPOSOME DRUG DELIVERY

13.4 INDUSTRY INSIGHTS

13.5 WINNING IMPERATIVES

13.6 COMPETITIVE DEVELOPMENTS

14 PEGYLATION TECHNOLOGIES14.1 INTRODUCTION14.2 DRIVERS & RESTRAINTS14.2.1 BIOLOGICAL DRUGS14.2.2 ENHANCED PHARMACOKINETIC PROPERTIES & REDUCED DOSAGE14.2.3 EXPENSIVE MANUFACTURING PROCEDURE14.3 OPPORTUNITY14.3.1 TECHNOLOGICAL ADVANCES14.4 INDUSTRY INSIGHTS14.5 WINNING IMPERATIVES

15 COMPETITIVE LANDSCAPE

15.1 INTRODUCTION

15.2 ANALYSIS OF TOP PLAYERS

15.2.1 STRATEGY

15.2.2 INJECTABLE DRUG DELIVERY DEVICES MARKET SHARE

15.2.2.1 Top injectable drug delivery device companies & revenues, by segment

15.3 WINNING IMPERATIVES

15.3.1 ALLIANCES

15.3.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY

15.3.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS

15.4 STRATEGIC RECOMMENDATIONS

16 GEOGRAPHIC ANALYSIS16.1 INTRODUCTION16.2 NORTH AMERICA16.3 EUROPE16.4 ASIA16.5 REST OF THE WORLD (ROW)16.6 DECISION SUPPORT DATABASE

17 COMPANY PROFILES

17.1 3M COMPANY

17.1.1 OVERVIEW

17.1.2 FINANCIALS

17.1.3 PRODUCTS & SERVICES

17.1.4 STRATEGY

17.1.5 DEVELOPMENTS

17.2 ALKERMES, INC

17.2.1 OVERVIEW

17.2.2 FINANCIALS

17.2.3 PRODUCTS & SERVICES

17.2.4 STRATEGY

17.2.5 DEVELOPMENTS

17.3 ALTEA THERAPEUTICS INC.

17.3.1 OVERVIEW

17.3.2 PRODUCTS & SERVICES

17.3.3 STRATEGY

17.3.4 DEVELOPMENTS

17.4 ANTARES PHARMA INC.

17.4.1 OVERVIEW

17.4.2 FINANCIALS

17.4.3 PRODUCTS & SERVICES

17.4.4 STRATEGY

17.4.5 DEVELOPMENTS

17.5 A.P. PHARMA, INC.

17.5.1 OVERVIEW

17.5.2 FINANCIALS

17.5.3 PRODUCTS & SERVICES

17.5.4 STRATEGY

17.5.5 DEVELOPMENTS

17.6 APPLIED PHARMA

17.6.1 OVERVIEW

17.6.2 PRODUCTS & SERVICES

17.6.3 STRATEGY

17.6.4 DEVELOPMENTS

17.7 ARADIGM CORPORATION

17.7.1 OVERVIEW

17.7.2 FINANCIALS

17.7.3 PRODUCTS & SERVICES

17.7.4 STRATEGY

17.7.5 DEVELOPMENTS

17.8 BAXTER BIOPHARMA

17.8.1 OVERVIEW

17.8.2 PRODUCTS & SERVICES

17.8.3 FINANCIALS

17.8.4 STRATEGY

17.8.5 DEVELOP0MENTS

17.9 BECTON, DICKINSON AND COMPANY

17.9.1 OVERVIEW

17.9.2 PRODUCT & SERVICES

17.9.3 FINANCIALS

17.9.4 STRATEGY

17.9.5 DEVELOPMENTS

17.10 BIOJECT INC.

17.10.1 OVERVIEW

17.10.2 FINANCIALS

17.10.3 PRODUCTS & SERVICES

17.10.4 STRATEGY

17.10.5 DEVELOPMENTS

17.11 BIOVAIL CORPORATION (VALEANT PHARMACEUTICALS INTERNATIONAL INC.)

17.11.1 OVERVIEW

17.11.2 PRODUCTS & SERVICES

17.11.3 FINANCIALS

17.11.4 STRATEGY

17.11.5 DEVELOPMENTS

17.12 CIMA LABS INC.

17.12.1 OVERVIEW

17.12.2 PRODUCTS & SERVICES

17.12.3 STRATEGY

17.12.4 DEVELOPMENTS

17.13 ELAN CORPORATION PLC.

17.13.1 OVERVIEW

17.13.2 FINANCIALS

17.13.3 PRODUCTS & SERVICES

17.13.4 STRATEGY

17.13.5 DEVELOPMENTS

17.14 ENDO PHARMACEUTICALS

17.14.1 OVERVIEW

17.14.2 FINANCIALS

17.14.3 PRODUCTS & SERVICES

17.14.4 STRATEGY

17.14.5 DEVELOPMENTS

17.15 EURAND PHARMACEUTICALS

17.15.1 OVERVIEW

17.15.2 FINANCIALS

17.15.3 PRODUCTS & SERVICES

17.15.4 STRATEGY

17.15.5 DEVELOPMENTS

17.16 FLAMEL TECHNOLOGIES, INC

17.16.1 OVERVIEW

17.16.2 FINANCIALS

17.16.3 PRODUCTS & SERVICES

17.16.4 STRATEGY

17.16.5 DEVELOPMENTS

17.17 JOHNSON & JOHNSON LTD.

17.17.1 OVERVIEW

17.17.2 FINANCIALS

17.17.3 PRODUCTS & SERVICES

17.17.4 STRATEGY

17.17.5 DEVELOPMENTS

17.18 KV PHARMACEUTICAL

17.18.1 OVERVIEW

17.18.2 FINANCIALS

17.18.3 PRODUCTS & SERVICES

17.18.4 STRATEGY

17.18.5 DEVELOPMENTS

17.19 LABOPHARM INC.

17.19.1 OVERVIEW

17.19.2 FINANCIALS

17.19.3 PRODUCTS & SERVICES

17.19.4 STRATEGY

17.19.5 DEVELOPMENTS

17.20 NANOPASS TECHNOLOGIES LTD.

17.20.1 OVERVIEW

17.20.2 PRODUCTS & SERVICES

17.20.3 STRATEGY

17.20.4 DEVELOPMENTS

17.21 NEKTAR THERAPEUTICS

17.21.1 OVERVIEW

17.21.2 FINANCIALS

17.21.3 PRODUCTS & SERVICES

17.21.4 STRATEGY

17.21.5 DEVELOPMENTS

17.22 QLT INC.

17.22.1 OVERVIEW

17.22.2 FINANCIALS

17.22.3 PRODUCTS & SERVICES

17.22.4 STRATEGY

17.22.5 DEVELOPMENTS

17.23 SKYEPHARMA PLC.

17.23.1 OVERVIEW

17.23.2 FINANCIALS

17.23.3 PRODUCTS & SERVICES

17.23.4 STRATEGY

17.23.5 DEVELOPMENTS

17.24 SURMODICS, INC.

17.24.1 OVERVIEW

17.24.2 PRODUCTS & SERVICES

17.24.3 FINANCIALS

17.24.4 STRATEGY

17.24.5 DEVELOPMENTS

17.25 VECTURA GROUP PLC

17.25.1 OVERVIEW

17.25.2 FINANCIALS

17.25.3 PRODUCTS & SERVICES

17.25.4 STRATEGY

17.25.5 DEVELOPMENTS

17.26 YPSOMED HOLDING AG

17.26.1 OVERVIEW

17.26.2 FINANCIALS

17.26.3 PRODUCTS & SERVICES

17.26.4 STRATEGY

17.26.5 DEVELOPMENTS

17.27 ZOGENIX, INC.

17.27.1 OVERVIEW

17.27.2 PRODUCTS & SERVICES

17.27.3 STRATEGY

17.27.4 DEVELOP0MENTS

APPENDIX U.S. PATENTSEUROPE PATENTSJAPAN PATENTS

LIST OF TABLES TABLE 1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS, 2008 – 2015 ($MILLION)

TABLE 2 DRUGS SET FOR PATENT EXPIRATION, 2010 – 2012

TABLE 3 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 4 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 5 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 7 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 8 GLOBAL HYDROGEL MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)

TABLE 9 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 10 GLOBAL ION EXCHANGE RESINS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 11 GLOBAL OSMOTIC PRESSURE CONTROLLED SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 12 GLOBAL DISSOLUTION/DIFFUSION SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 13 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 14 GLOBAL RESERVOIR SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 15 GLOBAL OTHER CONTROLLED RELEASE SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 16 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 17 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 18 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 19 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 20 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 21 GLOBAL ANTIBODY FRAGMENT CONJUGATE DELIVERY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 22 GLOBAL ANTIBODY ENZYME DIRECTED PRODRUG DELIVERY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 23 GLOBAL PEPTIDE TARGETED DRUG DELIVERY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 24 GLOBAL SMALL MOLECULE CONJUGATE DELIVERY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 25 GLOBAL OTHER TARGETING LIGANDS BASED DELIVERY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 26 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 27 GLOBAL ENCAPSULATION TECHNOLOGY MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 28 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 29 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 30 GLOBAL ENCAPSULATION MARKET IN TASTE MASKING, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 31 GLOBAL ENCAPSULATION MARKET IN FAST DISSOLVING, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 32 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 33 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY, 2008 – 2015

TABLE 34 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 35 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 36 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 37 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 38 GLOBAL OTHER TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 39 GLOBAL INHALER TECHNOLOGY MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 40 GLOBAL INHALER TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 41 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 42 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 43 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 44 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 45 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 46 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)

TABLE 47 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 48 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 49 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 50 GLOBAL PREFILLED SYRINGES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 51 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 52 GLOBAL SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 53 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 54 GLOBAL AUTO INJECTOR MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 55 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 56 GLOBAL PEN INJECTOR MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 57 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY

TABLE 58 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS, 2008 – 2015 ($MILLION)

TABLE 59 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 60 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 61 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCTS, (2008 – 2015)

TABLE 62 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 63 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 64 GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 65 GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 66 GLOBAL OCULAR IMPLANTS & OTHERS MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 67 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 68 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 69 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY, 2008 – 2015 ($MILLION)

TABLE 70 IMPACT ANALYSIS OF KEY MARKET DYNAMICS

TABLE 71 REVENUE ANALYSIS, 2008 – 2009

TABLE 72 ELAN TOTAL REVENUES BY DRUG, 2008 – 2010

TABLE 73 ALKERMES TOTAL REVENUES, BY DRUG, 2008 – 2010

TABLE 74 R&D EXPENDITURE, 2008 – 2009

TABLE 75 ELAN'S PIPELINE DRUGS

TABLE 76 BIOVAIL'S PIPELINE DRUGS

TABLE 77 ALKERMES'S PIPELINE DRUGS

TABLE 78 NEKTAR'S PIPELINE DRUGS

TABLE 79 SKYE PHARMA'S PIPELINE DRUGS

TABLE 80 TOP COMPANIES & THEIR STRATEGIES

TABLE 81 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENT ($MILLION)

TABLE 82 BAXTER BIOPHARMA REVENUES, BY SEGMENT

TABLE 83 YPSOMED - TOTAL REVENUES, BY SEGMENT ($MILLION)

TABLE 84 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION, 2008 – 2015

TABLE 85 NORTH AMERICAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT

TABLE 86 EUROPEAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT

TABLE 87 ASIAN TOP 10 DRUG DELIVERY TECHNOLOGIES

TABLE 88 REST OF THE WORLD TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET

TABLE 89 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY, 2009

TABLE 90 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY, 2009

TABLE 91 DIABETES PREVALENCE, BY GEOGRAPHY, 2009

TABLE 92 CANCER PREVALENCE, BY GEOGRAPHY, (2009)

TABLE 93 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY, (2009)

TABLE 94 ANEMIA PREVALENCE, BY GEOGRAPHY, 2009

TABLE 95 HEPATITIS-C PREVALENCE, BY GEOGRAPHY, 2009

TABLE 96 CROHN'S DISEASE PREVALENCE, BY GEOGRAPHY, 2009

TABLE 97 PSORIASIS PREVALENCE, BY GEOGRAPHY, 2009

TABLE 98 TOTAL REVENUES & R&D EXPENDITURE

TABLE 99 TOTAL REVENUES, BY GEOGRAPHY

TABLE 100 TOTAL REVENUES, 2006 – 2010

TABLE 101 SEGMENT SPECIFIC REVENUES ($MILLION)

TABLE 102 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)

TABLE 103 TOTAL REVENUES, BY GEOGRAPHY

TABLE 104 REVENUES, BY SEGMENTS

TABLE 105 TOTAL REVENUES & NET INCOME ($MILLION)

TABLE 106 TOTAL REVENUES, 2007 – 2009

TABLE 107 BAXTER BIOPHARMA – TOTAL REVENUES & R&D EXPENSES ($MILLION)

TABLE 108 BAXTER BIOPHARMA – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)

TABLE 109 BAXTER BIOPHARMA – TOTAL REVENUES, BY SEGMENTS ($MILLION)

TABLE 110 BAXTER BIOPHARMA – TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENTS ($MILLION)

TABLE 111 BECTON DICKINSON – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)

TABLE 112 BECTON DICKINSON – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)

TABLE 113 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENTS ($MILLION)

TABLE 114 BECTON DICKINSON – TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENTS ($MILLION)

TABLE 115 TOTAL REVENUES & R&D EXPENDITURE

TABLE 116 REVENUES, BY SEGMENTS ($MILLION)

TABLE 117 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)

TABLE 118 U.S REVENUES OF BIOVAIL, BY PRODUCTS ($MILLION)

TABLE 119 TOTAL PRODUCT REVENUES OF BIOVAIL PHARMACEUTICALS CANADA

TABLE 120 TOTAL REVENUES & R&D EXPENDITURE

TABLE 121 REVENUES, BY PRODUCTS

TABLE 122 TOTAL REVENUES & R&D EXPENDITURE

TABLE 123 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)

TABLE 124 PRODUCT SALES, BY THERAPEUTIC AREA

TABLE 125 REVENUES & R&D EXPENDITURE

TABLE 126 TOTAL REVENUES & R&D EXPENDITURE

TABLE 127 REVENUES, BY BUSINESS SEGMENTS

TABLE 128 REVENUES, BY PRODUCTS

TABLE 129 REVENUES, BY GEOGRAPHY ($MILLION)

TABLE 130 TOTAL REVENUES & EXPENDITURE

TABLE 131 TOTAL REVENUES & R&D EXPENDITURE

TABLE 132 NEKTAR – TOTAL REVENUES & R&D EXPENSES

TABLE 133 NEKTAR – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)

TABLE 134 QLT – TOTAL REVENUES & R&D EXPENSES ($MILLION)

TABLE 135 QLT – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)

TABLE 136 TOTAL REVENUES & R&D EXPENSES ($MILLION)

TABLE 137 SURMODICS INC. – TOTAL REVENUES & R&D EXPENSES ($MILLION)

TABLE 138 SURMODICS INC. – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)

TABLE 139 SURMODICS INC. – TOTAL REVENUES, BY SEGMENTS ($MILLION)

TABLE 140 TOTAL REVENUES & R&D EXPENDITURE

TABLE 141 YPSOMED - TOTAL REVENUES & R&D EXPENSES ($MILLION)

TABLE 142 YPSOMED - TOTAL REVENUES, BY SEGMENTS ($MILLION)

LIST OF FIGURES FIGURE 1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES

FIGURE 2 TOP 10 DRUG DELIVERY TECHNOLOGIES – MARKET SHARE

FIGURE 3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY

FIGURE 4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN A DRUG LIFE CYCLE

FIGURE 5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS

FIGURE 6 DRUG DELIVERY MARKET STAKEHOLDERS

FIGURE 7 IMPACT OF MARKET DRIVERS & RESTRAINTS

FIGURE 8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES

FIGURE 9 PATENT ANALYSIS, BY SEGMENTS, (2004 – 2009)

FIGURE 10 PATENT ANALYSIS, BY ASSIGNEE, (2004 – 2009)

FIGURE 11 COMMON REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS

FIGURE 12 EVOLUTION OF CONTROLLED RELEASE TECHNOLOGIES

FIGURE 13 CONTROLLED RELEASE VS IMMEDIATE RELEASE

FIGURE 14 TARGETED THERAPY TYPES

FIGURE 15 EVOLUTION OF ENCAPSULATION TECHNOLOGIES

FIGURE 16 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY

FIGURE 17 EVOLUTION OF INHALER TECHNOLOGY

FIGURE 18 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE

FIGURE 19 COMPETITIVE DEVELOPMENTS, 2007 – JUNE 2010

FIGURE 20 COMPETITIVE DEVELOPMENTS, BY SEGMENTS, 2007 – JUNE 2010

FIGURE 21 REVENUE ANALYSIS, 2008 – 2009

FIGURE 22 CONTROLLED RELEASE, DRUG FORMULATION – MARKET SHARE

FIGURE 23 R&D EXPENDITURE, 2008 – 2009

FIGURE 24 INJECTABLE DRUG DELIVERY DEVICES, MARKET SHARE

FIGURE 25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET

FIGURE 26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – NORTH AMERICA

FIGURE 27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – EUROPE

FIGURE 28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ASIA

FIGURE 29 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ROW

To order this report:Drug_Delivery_Technology Industry: Top 10 Drug Delivery Technologies (2010 - 2015)

Contact
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
2. Injectable Drug Delivery to 2016
3. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
4. Philips continues to improve access to treatment for common cause of death in the U.S. with the delivery of its one-millionth AED
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. GeNO LLC Receives Four Additional Patents for Inhaled Nitric Oxide Delivery
7. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
8. GeNO LLC Receives FDA Marketing Clearance For Its Inhaled Nitric Oxide Drug Delivery Device
9. AHM Announces New SVP Product Delivery
10. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
11. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for certain ... Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... Feb. 12, 2016  Memorial Hermann Health System has ... Howard to bring a one-of-a-kind experience to pediatric ... cutting-edge technologies such as 360-degree video and Google Cardboard, ... then literally – giving the patients and their families ... was all caught on video . ...
(Date:2/12/2016)... , Feb. 12, 2016 On Thursday, Feb. ... Surgery at St. David,s North Austin Medical Center successfully ... ® Xi ® Surgical System with Trumpf ... Thiru Lakshman , M.D., colorectal surgeon at ... proctocolectomy utilizing Integrated Table Motion technology, which seamlessly combines ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... The ... Recovery, the leading national organization representing the growing community of recovering individuals (now ... to include Family Recovery in policies addressing addiction. , Although many of ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Society (INS) states that vein visualization technology should be used to ensure patient ... around the world, the INS Standards mandate the use of vein visualization technology ...
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... DC (PRWEB) , ... February ... ... Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop ... The partnership will recruit top students from U.S. universities who will draw ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections ... Center. Almost 10,000 physical therapists across the country are expected to attend this annual ... chosen field and network with their colleagues. As in years past, HydroWorx is ...
Breaking Medicine News(10 mins):